In particular, in vitro T cell responses against a peptide derived from Bcl-xL was observed in cancer patients but not in healthy controls, and the subpopulation of T cells specific for the Bcl-xL peptide was cytotoxic against HLA-matched cancer cells of different histotypes [181]. The gene discussed is BCL2L1; the disease is cancer.